Drugs / NALIRIFOX plus targeted therapy
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07309289 Background | Jul 2025 → Mar 2029 expected | colorectal cancer | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NALIRIFOX plus targeted therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07309289 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07309289 ↗ |